Detalhe da pesquisa
1.
Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children's Hospital at Baylor College of Medicine.
Biomedicines
; 12(2)2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38397996
2.
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated.
Cancers (Basel)
; 15(4)2023 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831684
3.
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML.
Cancers (Basel)
; 14(24)2022 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551725
4.
Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds.
PLoS One
; 16(1): e0244863, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33411777
5.
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Blood Adv
; 5(23): 4864-4876, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543389
6.
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Blood Adv
; 3(24): 4215-4227, 2019 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31856268
7.
An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.
Leukemia
; 35(6): 1777-1781, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918044